human Papillomavirus: A New Vaccine by Helen K. Maher, PhD, rN, COHN-S, CCM, FAAOHN A n occupational health nurse notes that employees have been asking questions about recent news reports on human papillomavirus (HPV) and the new vaccine being offered during the past several weeks. She researches this topic to better answer their questions.
Papillomaviruses are tumor viruses that occur widely in animal species and are species specific (Weinstock, Berman, & Cates, 2004) . HPV is transmitted by direct skin-to-skin contact, and can exist on inanimate objects such as clothing or hard surfaces (Centers for Disease Control and Prevention [CDC], 2006) . HPV infection of the genital area is the most common human sexually transmitted infection in the United States, with more than half of sexually active individuals infected with HPV (Koutsky, 1997) . In most cases, HPV infections are not serious. These individuals are often asymptomatic, and the infection resolves over time without treatment. In some individuals, HPV infection can result in genital warts, Pap test abnormalities, or, rarely, cervical cancer (CDC, 2006) . HPV has been detected in 99% of cervical cancers worldwide and research indicates that HPV causes almost all cases of cervical cancer (Parkin, Bray, & Pisani, 2005) .
In females, risk factors associated with acquiring HPV infection include age younger than 25 years, multiple sexual partners, first sexual intercourse at 16 years or younger, and male partners who have or have had multiple sexual partners (CDC, 2006) .
Approximately 10% of females infected with HPV will develop persistent infection (CDC, 2006) . These females are at greatest risk for developing cervical cancer (CDC, 2006) .
Two primary risk factors influencing HPV persistence and progression to cervical cancer are lack of screening for cervical cancer and immunosuppression (CDC, 2006) . Over the past 40 years in the United States, annual Pap smears have been used to successfully identify cervical cancer, even when persistent HPV infection exists (CDC, 2006) .
Prevention of genital infection with HPV is essential in reducing the occurrence of genital warts, abnormal Pap smears, and cervical cancer (CDC, 2006) . A new quadrivalent vaccine, Gardasil (Merck & Co., Inc., Whitehouse Station, NJ), protects against four types of HPV responsible for 70% of cervical cancers and 90% of genital warts (CDC, 2006) . The vaccine is made from non-infectious HPV and does not contain thimerosal or mercury. It is administered in a series of three injections (0, 2, and 6 months). The recommended target group is girls 11 to 12 years old. It can be administered as early as 9 years and up to 26 years (CDC, 2006) . The vaccine should be provided prior to the onset of sexual activity. Screening for cervical cancer should also be initiated at this time (CDC, 2006) . The dura-tion of the vaccine's protection is still being determined. Current studies indicate that it is effective for at least 5 years-the length of these studies (CDC, 2006) .
Males also acquire HPV infections. Although HPV infections are common in males, HPV cancers are rare (CDC, 2006) . Currently, no recommendations exist to immunize males, although studies are ongoing.
The vaccine will not replace detection strategies such as annual Pap smears or prevention strategies such as using condoms, delaying sexual activity, or limiting the number of sexual partners (CDC, 2006) .
The occupational health nurse summarizes the material she has reviewed and posts this summary on the local health care website for employees to access. She encourages employees to share this information with teenagers and school nurses at middle and high schools.
